Our primary mission in establishing the Familial Breast Cancer Resource is to reduce the incidence, morbidity and mortality of breast cancer. To this end, the resource will be used to identify and study genetic markers of breast cancer susceptibility, and to offer high-risk women participation in cancer screening and prevention trials. Index cases of familial breast cancer are identified from our own tumor bank, physician referral, direct media solicitation, screening of mammography reports, and other sources. Accruals have exceeded our original projections substantially. The database currently includes 223 families representing 12,137 individuals, including 707 members with a history of breast cancer. Data collection includes well-documented degrees expanded to include second order relatives of all breast cancer cases. Data items include demographic and contact information as well as clinical information on all cancers, and all benign breast conditions. During the next funding period we propose to place additional emphasis on review and verification of clinical data and on recruitment of Hispanic families. There is a well-established cooperative relationship between the resource and local breast cancer trials (e.g. NSABP Breast Cancer Prevention Trial) so that trial participants with a positive family history are referred to the resource and the resource refers interested high risk patients to the trial. In addition to the databases, the resource also includes tissue banks. After obtaining informed consent, blood samples are obtained from key members of families with 3 or more affected members for banking as cryopreserved peripheral blood lymphocytes (PBL's) and frozen serum. The bank currently contains 113 PBL and serum samples representing 30 families. An additional 300 individuals are already targeted but not yet drawn. Procedures for handling informed consents and drawing bloods, both locally and out of town, for processing bloods, as well as all of the associated computer inventories and tracking systems, are well- established. We propose to continue this activity during the next funding period. Additionally, for affected members, we will retrieve archival tissue samples. In Project 4 of this application we propose to use DNA from banked PBL's to examine several tumor suppressor genes implicated in both hereditary and sporadic breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058183-05
Application #
5209188
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
1996
Total Cost
Indirect Cost
Guarducci, Cristina; Bonechi, Martina; Benelli, Matteo et al. (2018) Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. NPJ Breast Cancer 4:38
Rimawi, Mothaffar F; De Angelis, Carmine; Contreras, Alejandro et al. (2018) Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat 167:731-740
Sukumaran, Sujita; Watanabe, Norihiro; Bajgain, Pradip et al. (2018) Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. Cancer Discov 8:972-987
Kaochar, Salma; Mitsiades, Nicholas (2018) A Novel Mechanism to Drive Castration-Resistant Prostate Cancer. Trends Endocrinol Metab 29:366-368
Bhat, Raksha R; Yadav, Puja; Sahay, Debashish et al. (2018) GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer. Breast Cancer Res Treat 170:279-292
Hertz, D L; Kidwell, K M; Hilsenbeck, S G et al. (2017) CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study. Breast Cancer Res Treat 166:277-287
Yu, L; Liang, Y; Cao, X et al. (2017) Identification of MYST3 as a novel epigenetic activator of ER? frequently amplified in breast cancer. Oncogene 36:2910-2918
Guven, Adem; Villares, Gabriel J; Hilsenbeck, Susan G et al. (2017) Carbon nanotube capsules enhance the in vivo efficacy of cisplatin. Acta Biomater 58:466-478
Veeraraghavan, Jamunarani; De Angelis, Carmine; Reis-Filho, Jorge S et al. (2017) De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. Breast 34 Suppl 1:S19-S26
Xu, Xiaowei; De Angelis, Carmine; Burke, Kathleen A et al. (2017) HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res 23:5123-5134

Showing the most recent 10 out of 306 publications